Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Relypsa nets $79.7mm through its IPO

Executive Summary

Relypsa Inc. (cardiovascular and metabolic therapeutics) netted $79.7mm through the initial public offering of 7.8mm common shares (including a partial exercise of the overallotment) at $11. The company had originally planned to sell 6.9mm shares between $16-19. Some of Relypsa's current shareholders and one of its executive officers agreed to purchase a total of 1.8mm shares (about $19.9mm) through the financing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies